New Three-Drug cocktail targets Hard-to-Treat bladder cancer
NCT ID NCT05335941
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This phase 2 trial tests a combination of three drugs—pemetrexed, etrumadenant, and zimberelimab—in 10 people with advanced bladder cancer that has a specific genetic change (MTAP deficiency) and has already been treated with immunotherapy. The goal is to see if the combo is safe and can shrink tumors. It is a small, early study at one cancer center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pemetrexed, etrumadenant, and zimberelimab
- What this could lead to
- If successful, this could offer a new treatment option for people with a specific type of advanced bladder cancer that has stopped responding to standard therapy.
- What could go wrong
- This is a very small, early-phase trial with only 10 participants at one center. The combination may cause significant side effects and may not prove effective in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tissue analysis may guide personalized cancer therapy
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Blood test vs. scalpel: could liquid biopsy replace tissue biopsies for cancer monitoring?
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?